$20.29
2.47% yesterday
Nasdaq, Sep 05, 10:14 pm CET
ISIN
US14888U1016
Symbol
CPRX

Catalyst Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other mem...
Neutral
GlobeNewsWire
10 days ago
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035
Neutral
GlobeNewsWire
12 days ago
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035
Neutral
Seeking Alpha
29 days ago
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Jeffrey Del Carmen - Executive VP & Chief Commercial Officer Michael W. Kalb - Executive VP, Treasurer & CFO Richard John Daly - President, CEO & Director William T.
Neutral
GlobeNewsWire
about one month ago
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% Yo Y, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year 2025 Total Revenue Guidance of $545 Million to $565 Million, Reflecting Broad-Based Growth and Sustained Demand FIRDAPSE® Q2 2025 Net Product R...
Neutral
GlobeNewsWire
about one month ago
CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guide...
Neutral
GlobeNewsWire
about one month ago
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors.
Neutral
GlobeNewsWire
about 2 months ago
The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today